MicroPort NeuroScientific

MicroPort NeuroScientific OCF Margin

The Operating Cash Flow Margin of MicroPort NeuroScientific (2172.HK) as of Oct 27, 2026 is 26.24 %. In the previous year, Operating Cash Flow Margin was 37.34 % — a change of -29.73% (lower).

OCF Margin

26.24 %

YoY

-29.73%

Last updated:

Operating Cash Flow Margin of MicroPort NeuroScientific is 2025 26.24 % . Operating Cash Flow Margin of MicroPort NeuroScientific was 2024 37.34 % . It decreases by -29.73% lower compared to the previous year.

The MicroPort NeuroScientific OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2019
30.83 CNY
Jan 1, 2020
21.28 CNY
Jan 1, 2021
41.12 CNY
Jan 1, 2022
48.07 CNY
Jan 1, 2023
27.16 CNY
Jan 1, 2024
37.34 CNY
Jan 1, 2025
26.24 CNY
The MicroPort NeuroScientific OCF Margin history
YEAROCF MarginYoY
26.24 %-29.73%
37.34 %+37.47%
27.16 %-43.50%
48.07 %+16.89%
41.12 %+93.20%
21.28 %-30.97%
30.83 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

MicroPort NeuroScientific Stock analysis

What does MicroPort NeuroScientific do? MicroPort NeuroTech Ltd. generates revenue through the research, development, manufacturing, and sales of neuro-interventional medical devices. Its main products include embolization coils, flow-diverting stents, and stent grafts, targeting three key areas of neurovascular diseases: hemorrhagic stroke, cerebral atherosclerotic stenosis, and acute ischemic stroke. The company serves domestic and overseas markets, with its products primarily used by hospitals and healthcare providers for treating brain diseases. The firm's focus on neurovascular disease solutions drives its commercial strategy. The company operates under the brand MicroPort NeuroTech Ltd., which is part of the broader MicroPort group. It targets healthcare institutions globally, particularly those specializing in neurovascular care. The firm's product portfolio addresses critical treatment needs in neurovascular conditions, aligning with the growing demand for advanced medical devices in stroke management. Revenue streams are derived from direct sales of its medical devices to hospitals and clinics. MicroPort NeuroTech Ltd. focuses on the domestic and overseas markets, with its products designed for specific neurovascular applications. The company's revenue model relies on the sale of embolization coils, flow-diverting stents, and stent grafts to healthcare providers. These products are essential for treating conditions like hemorrhagic stroke and acute ischemic stroke, which are major causes of neurological disability. The firm's strategy emphasizes innovation in neuro-interventional solutions to capture market share in both local and international segments. MicroPort NeuroScientific is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MicroPort NeuroScientific stock

Operating Cash Flow Margin of MicroPort NeuroScientific is 26.24 % in 2025.

Operating Cash Flow Margin of MicroPort NeuroScientific changed from 37.34 % to 26.24 %, representing a -29.73% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin MicroPort NeuroScientific since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's MicroPort NeuroScientific with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — MicroPort NeuroScientific

All Key Metrics — MicroPort NeuroScientific